| __timestamp | Viking Therapeutics, Inc. | Xenon Pharmaceuticals Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 1244910 | 5496000 |
| Thursday, January 1, 2015 | 5029636 | 9786000 |
| Friday, January 1, 2016 | 4846776 | 6792000 |
| Sunday, January 1, 2017 | 5329003 | 7313000 |
| Monday, January 1, 2018 | 7121000 | 8382000 |
| Tuesday, January 1, 2019 | 9128000 | 10803000 |
| Wednesday, January 1, 2020 | 10731000 | 12944000 |
| Friday, January 1, 2021 | 10701000 | 21967000 |
| Saturday, January 1, 2022 | 16121000 | 32810000 |
| Sunday, January 1, 2023 | 37021000 | 46542000 |
Unlocking the unknown
In the competitive world of biotechnology, managing Selling, General, and Administrative (SG&A) expenses is crucial for financial health. Viking Therapeutics, Inc. and Xenon Pharmaceuticals Inc. have been navigating this challenge since 2014. Over the past decade, Viking Therapeutics has shown a remarkable 2,870% increase in SG&A expenses, peaking at $37 million in 2023. Meanwhile, Xenon Pharmaceuticals has seen a 747% rise, reaching $46 million in the same year.
While both companies have increased their spending, Xenon consistently outpaces Viking, suggesting a more aggressive investment in administrative and sales functions. However, Viking's rapid growth in recent years indicates a strategic shift. Investors and analysts should consider these trends when evaluating the companies' operational efficiencies and future growth potential. Understanding these dynamics can provide valuable insights into each company's strategic priorities and market positioning.
Who Optimizes SG&A Costs Better? Sanofi or Viking Therapeutics, Inc.
SG&A Efficiency Analysis: Comparing Gilead Sciences, Inc. and Viking Therapeutics, Inc.
Incyte Corporation and Viking Therapeutics, Inc.: SG&A Spending Patterns Compared
Breaking Down SG&A Expenses: Madrigal Pharmaceuticals, Inc. vs Xenon Pharmaceuticals Inc.
SG&A Efficiency Analysis: Comparing Alkermes plc and Xenon Pharmaceuticals Inc.
Who Optimizes SG&A Costs Better? Apellis Pharmaceuticals, Inc. or Viking Therapeutics, Inc.
Operational Costs Compared: SG&A Analysis of Viking Therapeutics, Inc. and CRISPR Therapeutics AG
SG&A Efficiency Analysis: Comparing Viking Therapeutics, Inc. and MorphoSys AG
Cost Management Insights: SG&A Expenses for Viking Therapeutics, Inc. and Supernus Pharmaceuticals, Inc.
Comparing SG&A Expenses: Viking Therapeutics, Inc. vs ImmunityBio, Inc. Trends and Insights
Viking Therapeutics, Inc. and Evotec SE: SG&A Spending Patterns Compared
Who Optimizes SG&A Costs Better? CRISPR Therapeutics AG or Xenon Pharmaceuticals Inc.